Rocuronium: Difference between revisions

No edit summary
(One intermediate revision by the same user not shown)
Line 37: Line 37:
==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
Anaphylaxis
*[[Anaphylaxis]]


===Common===
===Common===
Cardiovascular:  hypertension (0.1% to 2%)Hypotension (0.1% to 2%)Tachycardia (1% to 5.3%)
*Cardiovascular:  [[hypertension]] (0.1% to 2%)
Dermatologic:  Pain at injection site
*[[Hypotension]] (0.1% to 2%)
Respiratory:  Increased pulmonary vascular resistance (24%)
*[[Tachycardia]] (1% to 5.3%)
*Dermatologic:  Pain at injection site
*Respiratory:  Increased pulmonary vascular resistance (24%)


==Pharmacology==
==Pharmacology==
Line 52: Line 54:
==See Also==
==See Also==
*[[Critical care quick reference]]
*[[Critical care quick reference]]
*Reversal agent: [[Sugammadex]]


==References==
==References==

Revision as of 03:21, 5 January 2017

See critical care quick reference for drug doses by weight.

General

  • Type: Neuromuscular blocker, Non-Depolarizing, Fast Onset, Intermediate Lasting
  • Dosage Forms: IV
  • Common Trade Names: Zemuron

Adult Dosing

RSI

  • 0.6 to 1.2mg/kg IV (actual body weight)

Maintenance Bolus Dosing

  • 0.1 to 0.2mg/kg IV

Infusion

  • 10 to 12 mcg/kg/min

Pediatric Dosing

See critical care quick reference for drug doses by weight.

RSI

  • 0.6 to 1.2mg/kg IV (actual body weight)

Maintenance Bolus Dosing

  • 0.1 to 0.2mg/kg IV

Infusion

  • 10 to 12 mcg/kg/min

Special Populations

  • Pregnancy Rating: C
  • Lactation: Infant risk cannot be ruled out
  • Renal Dosing (half life approximately 1 hour longer if renal transplant patient)
    • Adult
    • Pediatric
  • Hepatic Dosing (half life approximately 3 hours longer with liver dysfunction)
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

  • Cardiovascular: hypertension (0.1% to 2%)
  • Hypotension (0.1% to 2%)
  • Tachycardia (1% to 5.3%)
  • Dermatologic: Pain at injection site
  • Respiratory: Increased pulmonary vascular resistance (24%)

Pharmacology

  • Half-life: Variable by age, but anywhere from 30 minutes to 2 hours.
  • Metabolism: Metabolite is 17-desacetyl-rocuronium
  • Excretion: Primary route is fecal. Renal also.
  • Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Intermediate duration with dose dependant rapid to intermediate onset. Competes for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors like those found in organophosphates antagonize this action

See Also

References